NO154055B - ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE ISOPROPYLAMINO-PYRIMIDINE HYDROXY DERIVATIVES. - Google Patents

ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE ISOPROPYLAMINO-PYRIMIDINE HYDROXY DERIVATIVES. Download PDF

Info

Publication number
NO154055B
NO154055B NO801234A NO801234A NO154055B NO 154055 B NO154055 B NO 154055B NO 801234 A NO801234 A NO 801234A NO 801234 A NO801234 A NO 801234A NO 154055 B NO154055 B NO 154055B
Authority
NO
Norway
Prior art keywords
residue
general formula
methyl
compound
hydroxy
Prior art date
Application number
NO801234A
Other languages
Norwegian (no)
Other versions
NO154055C (en
NO801234L (en
Inventor
Andre Esanu
Original Assignee
Soc D Etudes Prod Chimique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soc D Etudes Prod Chimique filed Critical Soc D Etudes Prod Chimique
Publication of NO801234L publication Critical patent/NO801234L/en
Publication of NO154055B publication Critical patent/NO154055B/en
Publication of NO154055C publication Critical patent/NO154055C/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)

Description

Fremgangsmåte til fremstilling av nye terapeutisk virksomme piperidinderivater. Process for the production of new therapeutically effective piperidine derivatives.

Nærværende oppfinnelse vedrører fremgangsmåte til fremstilling av nye piperidinderivater med verdifulle farmako-logiske egenskaper. The present invention relates to a process for the production of new piperidine derivatives with valuable pharmacological properties.

Det ble overraskende funnet at piperidinderivater med den generelle formel I, It was surprisingly found that piperidine derivatives of the general formula I,

hvor R, betyr hydrogen, en alkylrest med i høyden 12 karbonatomer, en alkylenrest med 3—5 karbonatomer, cyklopropylmethylresten eller en fenyl-alkylrest med 7—9 karbonatomer, R2 hydrogen eller methylresten, og Rs en alkylrest med i høyden 4 karbonato- where R means hydrogen, an alkyl residue with a maximum of 12 carbon atoms, an alkylene residue with 3-5 carbon atoms, the cyclopropylmethyl residue or a phenyl-alkyl residue with 7-9 carbon atoms, R2 hydrogen or the methyl residue, and Rs an alkyl residue with a maximum of 4 carbon atoms

mer, fenylresten, en fenyl-alkylrest med 7—9 karbonatomer, styrylresten eller sammen med R, en eventuelt met-hylsubstituert trimethylen- til hexa-methylenrest, og R,, hydrogen eller more, the phenyl residue, a phenyl-alkyl residue with 7-9 carbon atoms, the styryl residue or together with R, an optionally methyl-substituted trimethylene to hexamethylene residue, and R,, hydrogen or

methylresten, the methyl residue,

og deres salter med uorganiske eller orga- and their salts with inorganic or organic

niske syrer innehar verdifulle farmakolo- nic acids have valuable pharmacological

giske egenskaper, i særdeleshet en utmer- physical properties, in particular an excellent

ket analgetisk virkning ved oral som paren- ked analgesic effect by oral as paren-

teral administrasjon og sterk antitussiv virkning. I motsetning til andre analgetika innehar de ingen para-sympatikolytiske egenskaper, men virker snarere parasym-patikomimetisk. De er samtidig relativt lite toksiske og egner seg derfor f. eks. til lind- teral administration and strong antitussive effect. Unlike other analgesics, they have no parasympatholytic properties, but rather act parasympathomimetic. At the same time, they are relatively non-toxic and are therefore suitable for e.g. to lind-

ring og fjerning av smerter av forskjellig opprinnelse og også ved hosteirritasjoner. ring and removal of pain of various origins and also in case of cough irritations.

Forsøksrapport. Trial report.

1. Analgetisk virkning. 1. Analgesic effect.

a) Prøvede forbindelser. a) Tested compounds.

I. l-(l'-methyl-4'-hydroxy-4'-piperidyl)-2-propanon (citrat). II. l-(l'-methyl-4'-hydroxy-4'-piperidyl)-2-pentanon (citrat). I. 1-(1'-Methyl-4'-hydroxy-4'-piperidyl)-2-propanone (citrate). II. 1-(1'-methyl-4'-hydroxy-4'-piperidyl)-2-pentanone (citrate).

III. Acetylsalicylsyre. III. Acetylsalicylic acid.

b) Forsøk ifølge Friebel. b) Experiment according to Friebel.

Den analgetiske virkning bestemmes The analgesic effect is determined

efter metode av Gross, hvorved halene på according to the method of Gross, whereby the tails on

hvite mus irriteres med apparatet av Fri- white mice are irritated with the apparatus of Fri-

ebel og Reichle (Heiv. Physicol. u. Pharma- ebel and Reichle (Heiv. Physicol. u. Pharma-

kol. Acta 5 C 31 (1947)) ved termisk be-stråling. col. Acta 5 C 31 (1947)) by thermal radiation.

Den ifølge Gross definerte reaksjons- According to Gross, the reaction

tid ved den ovenfor nevnte irritasjon bestemmes på forskjellige grupper på 10—20 time at the above-mentioned irritation is determined in different groups of 10-20

dyr, av hvilke hvert veier 18—25 g, 30 og 15 minutter før administrasjonen av prøve-substansene. Derefter administreres alle dyregruppene en suspensjon av prøvesub- animals, each weighing 18-25 g, 30 and 15 minutes before the administration of the test substances. Then all animal groups are administered a suspension of sample sub-

stansene med gummi arabicum i vann i doser på 200 mg/kg peroralt. I løpet av den første time efter administrasjonen av prø-vesubstansene bestemmes hvert kvarter den gjennomsnittlige reaksjonstid for hver dyregruppe og derefter fastslås differan- the punches with gum arabic in water in doses of 200 mg/kg orally. During the first hour after the administration of the test substances, the average reaction time for each animal group is determined every quarter of an hour and then differences

sen mellom den gjennomsnittlige reaksjonstid efter 30, 45 og 60 minutter på den ene side og den gjennomsnittlige reaksjonstid før administrasjonen av prøvesubstan-sene på den annen side, uttrykt i prosent av de sistnevnte. difference between the average reaction time after 30, 45 and 60 minutes on the one hand and the average reaction time before the administration of the test substances on the other hand, expressed as a percentage of the latter.

c) Resultater. c) Results.

d) Konklusjon. d) Conclusion.

De ifølge oppfinnelsen fremstillbare Those according to the invention that can be produced

forbindelser ifølge nærværende krav viser som milde analgetica, overfor acetylsalicylsyre en stor overlegenhet. compounds according to the present claim show, as mild analgesics, a great superiority over acetylsalicylic acid.

I forbindelsene med den generelle formel I og de tilhørende, videre nedenfor nevnte utgangsstoffer betyr R, f. eks. hydrogen, alkylrestene som methyl-, ethyl-, n-propyl-, isopropyl-, n-butyl-, isobutyl-, sek. butyl-, n-amyl-, isoamyl-, n-hexyl-, n-octyl-, n-decyl-, eller n-dodecylresten; al-kenylrestene som allyl-, crotyl-, methallyl-, eller Y.ydimethylallylresten; cyklopropylmethylresten, eller fenylalkylrestene som benzyl-, (3-fenyl-ethyl- eller y-fenyl-pro-pylr esten. In the compounds of the general formula I and the associated starting substances mentioned further below, R means, e.g. hydrogen, the alkyl residues such as methyl-, ethyl-, n-propyl-, isopropyl-, n-butyl-, isobutyl-, sec. the butyl, n-amyl, isoamyl, n-hexyl, n-octyl, n-decyl, or n-dodecyl residue; the alkenyl radicals such as the allyl, crotyl, methallyl, or Y.ydimethylallyl radical; the cyclopropylmethyl residue, or the phenylalkyl residues such as benzyl-, (3-phenyl-ethyl- or γ-phenyl-propyl-resten.

R., er alene f. eks. methyl-, ethyl-, n-propyi-, isopropyl-, n-butyl-, isobutyl-, sek. butyl-, tert. butyl-, fenyl-, benzyl-, a-methyl-benzyl-, a-fenyl-ethyl-, p-fenyl-ethyl-eller styryl-resten ((3-fenyl-vinyl-rest). R., is alone e.g. methyl-, ethyl-, n-propyl-, isopropyl-, n-butyl-, isobutyl-, sec. butyl-, tert. butyl-, phenyl-, benzyl-, α-methyl-benzyl-, α-phenyl-ethyl-, p-phenyl-ethyl- or styryl-residue ((3-phenyl-vinyl-residue).

R3 danner videre sammen med R2 f. eks. trimethylen-, tetramethylen-, 1-methyl-tetramethylen-, pentamethylen- eller hexamethylenresten. R3 further forms together with R2, e.g. trimethylene, tetramethylene, 1-methyl-tetramethylene, pentamethylene or hexamethylene residue.

Forbindelsen med den generelle formel I lar seg fremstille som det videre ble funnet ut på overraskende enkel måte, idet man omsetter et 4-piperidon med den generelle formel II The compound with the general formula I can be prepared, as was further discovered, in a surprisingly simple way, by reacting a 4-piperidone with the general formula II

med et keton med den generelle formel III with a ketone of the general formula III

R:1-CO-CH2-R2 III hvor R,, R2, R3 og R4 har den under den R:1-CO-CH2-R2 III where R1, R2, R3 and R4 have the under

generelle formel I angitte betydning, i nærvær av et i homogen eller heterogen general formula I stated meaning, in the presence of a i homogeneous or heterogeneous

fase foreliggende basisk eller surt stoff. Som basiske kondensasjonsmidler kommer på den ene side uorganiske baser som natriumhydroxyd og organiske baser som piperidin, piperazin, og i vannfritt medium eller i fravær av oppløsningsmidler også alkalimetallalkoholater og på den annen side basiske ioneutvekslere, fortrinnsvis slike med kvaternære ammoniumgrupper som f. eks. Amberlit IRA 400 (OH-), men også svakere basiske som Amberlit IR 4B på tale, hvilke kan anvendes ved satsvis eller eventuelt også kontinuerlig fremgangsmåte. Som reaksjonsmedium kan tjene alt efter oppløseligheten av utgangsstoffene f. eks. vann, en vannholdig og endelig også en vannfri lavere alkanol eller et annet po-lart oppløsningsmiddel. phase present basic or acidic substance. As basic condensation agents, on the one hand, inorganic bases such as sodium hydroxide and organic bases such as piperidine, piperazine, and in anhydrous medium or in the absence of solvents also alkali metal alcoholates and on the other hand basic ion exchangers, preferably those with quaternary ammonium groups such as e.g. Amberlit IRA 400 (OH-), but also weaker basic ones such as Amberlit IR 4B in speech, which can be used in a batch or possibly also continuous process. Depending on the solubility of the starting materials, e.g. water, an aqueous and finally also an anhydrous lower alkanol or other polar solvent.

Som eksempler på sure kondensasjonsmidler kan nevnes ammoniumsalter som f. eks. ammoniumacetat, alene eller i kom-binasjon med iseddik og eventuelt et inert oppløsningsmiddel som f. eks. benzol, såvel som sure ioneutvekslere som f. eks. Amberlit IR 120 H+-form, i vann eller en vannholdig lavere alkanol som reaksjonsmedium. As examples of acidic condensing agents, ammonium salts such as e.g. ammonium acetate, alone or in combination with glacial acetic acid and possibly an inert solvent such as e.g. benzene, as well as acidic ion exchangers such as Amberlit IR 120 H+ form, in water or an aqueous lower alkanol as reaction medium.

Kondensasjonene finner sted fortrinnsvis ved værelsetemperatur til moderat forhøyet temperatur, d.v.s. det fore-trukne temperaturområde ligger mellom ca. 20 og 60°. Ved høyere temperaturer, f. eks. ved koketemperatur for det anvendte oppløsnings- eller fortynningsmiddel inntrer efter inntrådt dannelse av hydroxy-forbindelsen i alminnelighet vannavspaltning, hvorved som hovedprodukt den tilsvarende forbindelse med cyklisk dobbelt-binding oppstår. Selvfølgelig er inntreffel-sen av vannavspaltning ikke bare avhengig av reaksjonstemperaturen. men også av typen utgangsstoffer, kondensasjonsmidlet og oppløsningsmidlet såvel som konsentra-sjonen og reaksjonstiden, slik at den nevnte øvre temperaturgrense på 60° for utvin-ningen av hydroxyforbindelseri med den generelle formel I utelukkende er å vur-dere som retningslinje. The condensations take place preferably at room temperature to a moderately elevated temperature, i.e. the preferred temperature range is between approx. 20 and 60°. At higher temperatures, e.g. at the boiling temperature of the solvent or diluent used, after the formation of the hydroxy compound usually occurs, water is split off, whereby the corresponding compound with a cyclic double bond is produced as the main product. Of course, the occurrence of water splitting is not only dependent on the reaction temperature. but also of the type of starting materials, the condensing agent and the solvent as well as the concentration and reaction time, so that the aforementioned upper temperature limit of 60° for the extraction of hydroxy compounds with the general formula I is to be considered exclusively as a guideline.

Overraskende og for at den foran nevnte fremgangsmåte skal falle heldig ut er den konstatering avgjørende, at ved bland-inger av ketoner med den generelle formel II og III som begge inneholder såvel reaksjonsdyktige carbonylgrupper som også methylengrupper, under de forskjelligste betingelser for aldolkondensasj onen trer selvkondensasjonen av reaksjonskompo-nentene tilbake overfor en bestemt blandet kondensasjon, således at forbindelsene med den generelle formel I oppstår som hoved-produkter, mens ved aldolkondensasjoner med 2 forskjellige reaksjonskomponenter i alminnelighet bare da i noen grad ens-artete reaksjonsprodukter er å vente når et aldehyd kondenseres med et keton eller med et annet forskjelligartet aldehyd. Surprisingly, and in order for the aforementioned method to turn out to be successful, the finding is crucial that in mixtures of ketones with the general formula II and III, which both contain reactive carbonyl groups as well as methylene groups, under the most diverse conditions for aldol condensation, self-condensation takes place of the reaction components back to a specific mixed condensation, so that the compounds with the general formula I occur as main products, while in aldol condensations with 2 different reaction components, in general, only somewhat similar reaction products are to be expected when an aldehyde is condensed with a ketone or with another different aldehyde.

Ved utgangsstoffene med den generelle formel II dreier det seg om de i 1-stilling eventuelt ifølge definisjonen substituerte 4-piperidoner og 3-methyl-4-piperidoner. Forbindelser med denne generelle formel er allerede kjente og videre fremstillbare på analog måte. Egnede utgangsstoffer med den generelle formel III er f. eks. methyl-alkyl-ketoner med rettkjedete eller forgrenede alkylgrupper, som f. eks. aceton, butanon, methyl-n-propyl-keton, methyl-isopropyl-keton, methyl-n-butyl-keton, methyl-isobutyl-keton, methyl-sek.butyl-keton og pinakolon, ved deres anvendelse oppstår forbindelser med et hydrogenatom Rt); videre diethylketon og ethyl-sek.alkyl-ketoner som ethyl-isopropyl-keton, hvilke gir forbindelser med den generelle formel I med en methylgruppe som R0 og videre cykloalkanoner, som cyklopentanon, cyklo-hexanon, cykloheptanon, og cyklooctanon, såvel som aromatisk-alifatiske og aralifa-tisk-alifatiske ketoner som acetofenon, propiofenon, benzyl-methyl-keton, (a-fenyl-ethyl)-methyl-keton, (|3-fenyl-ethyl)-methyl-keton, ( y- t enyl-propyl) -methyl-keton og benzalaceton. The starting substances with the general formula II are the 4-piperidones and 3-methyl-4-piperidones optionally substituted in the 1-position according to the definition. Compounds with this general formula are already known and can further be prepared in an analogous manner. Suitable starting substances with the general formula III are e.g. methyl alkyl ketones with straight-chain or branched alkyl groups, such as e.g. acetone, butanone, methyl-n-propyl-ketone, methyl-isopropyl-ketone, methyl-n-butyl-ketone, methyl-isobutyl-ketone, methyl-sec.butyl-ketone and pinacolone, their use results in compounds with a hydrogen atom Rt); further diethyl ketone and ethyl sec. alkyl ketones such as ethyl isopropyl ketone, which give compounds of the general formula I with a methyl group as R0 and further cycloalkanones, such as cyclopentanone, cyclohexanone, cycloheptanone and cyclooctanone, as well as aromatic aliphatic and araliphatic-aliphatic ketones such as acetophenone, propiophenone, benzyl-methyl-ketone, (a-phenyl-ethyl)-methyl-ketone, (|3-phenyl-ethyl)-methyl-ketone, (y-t enyl- propyl)-methyl ketone and benzalacetone.

Fremstillingen av forbindelsene med den generelle formel I kan også finne sted analogt en flertrinnet fremgangsmåte som i litteraturen foreslås som erstatning for den ikke gjennomførbare direkte aldol-kondensasjon mellom et keton og et aldehyd til tilsvarende umettet aldehyd. The preparation of the compounds with the general formula I can also take place analogously to a multi-step process that is proposed in the literature as a substitute for the impracticable direct aldol condensation between a ketone and an aldehyde to the corresponding unsaturated aldehyde.

Ifølge denne fremgangsmåte overfører man et ketimin (Schiffske base) med den generelle formel IV, According to this method, a ketimine (Schiff base) with the general formula IV is transferred,

hvor R- betyr en hydrokarbonrest, i særdeleshet cyklohexylresten, og R„ og R, har den under den generelle formel I angitte betydning, til dets alkalimetallforbindelse, isærdeleshet lithiumforbindelsen, omsetter sistnevnte med en forbindelse med den generelle formel V, hvor R,' har den under den generelle formel I for R, angitte betydning med unntagelse av hydrogen og R4 har den der angitte betydning, under vannfrie betingelser og hydrolyserer det erholdte addukt med den generelle formel VI, where R- means a hydrocarbon residue, in particular the cyclohexyl residue, and R„ and R, have the meaning given under the general formula I, to its alkali metal compound, especially the lithium compound, reacts the latter with a compound of the general formula V, where R,' has the meaning given under the general formula I for R, with the exception of hydrogen and R4 has the meaning given there, under anhydrous conditions and hydrolyzes the obtained adduct with the general formula VI,

hvor M betyr et alkalimetallatom, i særdeleshet et lithiumatom, og R,', R2, R3, R,, og R, har den under den generelle formel V, henholdsvis IV angitte betydning, where M means an alkali metal atom, in particular a lithium atom, and R,', R 2 , R 3 , R 1 , and R, has the meaning given under the general formula V, respectively IV,

under milde betingelser, fortrinnsvis i surt medium. F. eks. overføres et ketimin med den generelle formel IV i absolutt ether ved hjelp av lithium-diisopropylamin, som på sin side ble fremstilt av fenyl-lithium og diisopropylamin i ether, i kulde til dets lithiumforbindelse og det sistnevnte ut-gangsmateriale omsettes eventuelt i kulde i samme medium med en forbindelse med den generelle formel V. Fra det erholdte mellomprodukt som er et addukt, med den generelle formel VI og som ikke er søkt beskyttet, frisettes først ved hjelp av vann den tilsvarende hydroxyforbindelse og den sistnevnte hydrolyseres f. eks. ved hjelp av 2-n svovelsyre ved værelsetemperatur til moderat forhøyet temperatur på ca. 60°. under mild conditions, preferably in acidic medium. For example a ketimine of the general formula IV is transferred in absolute ether using lithium diisopropylamine, which in turn was prepared from phenyllithium and diisopropylamine in ether, in the cold to its lithium compound and the latter starting material is optionally reacted in the cold in the same medium with a compound of the general formula V. From the intermediate product obtained, which is an adduct, with the general formula VI and which has not been protected, the corresponding hydroxy compound is first released with the help of water and the latter is hydrolysed, e.g. using 2-n sulfuric acid at room temperature to a moderately elevated temperature of approx. 60°.

Det kan også anvendes svovelsyre med andre konsentrasjoner eller fortynnet saltsyre til hydrolysen, men i alle fall er ener-giske reaksjonsbetingelser å unngå, da el-lers vannavspaltning inntrer. De som utgangsstoffer med den generelle formel IV nødvendige ketiminer lar seg utvinne f. eks. ved oppvarmning av det tilsvarende keton med et primært amin, isærdeleshet cyklohexylamin, i et med vann azeotrop destillerende inert oppløsningsmiddel som toluol under adskillelse av det frisatte vann. En del av ketiminene lar seg rense ved destillasjon i høyvakuum, andre er ikke destillerbare uspaltet og videre-anvendes derfor som råprodukt. Sulfuric acid with other concentrations or diluted hydrochloric acid can also be used for the hydrolysis, but in any case energetic reaction conditions are to be avoided, as otherwise water separation occurs. The ketimines required as starting substances with the general formula IV can be extracted, e.g. by heating the corresponding ketone with a primary amine, especially cyclohexylamine, in an inert solvent distilling azeotropically with water such as toluene while separating the released water. Some of the ketimines can be purified by distillation in a high vacuum, others cannot be distilled uncleaved and are therefore further used as a raw product.

Ifølge et tredje alternativ oppnår man slike forbindelser med den generelle formel I i hvilke resten R:! oppviser en methylen-gruppe ved dens bindingsstilling med ear-bonylgruppen, idet man behandler en forbindelse med den generelle formel VII, According to a third alternative, such compounds of the general formula I are obtained in which the radical R:! presents a methylene group at its bond position with the ear-bonyl group, treating a compound of the general formula VII,

hvor R," betyr en rest tilsvarende definisjonen for R, eller benzyloxycarbonylresten og R.s' hydrogen eller en rest som ved tilføyelsen av methylengruppen -CH2- tilsvarer en under den generelle formel I definert rest R3, og hvor Rg og R., har den ovenfor angitte where R" means a residue corresponding to the definition for R, or the benzyloxycarbonyl residue and R.s' hydrogen or a residue which, by the addition of the methylene group -CH2-, corresponds to a residue R3 defined under the general formula I, and where Rg and R., have the above indicated

betydning, importance,

med en kvikksølvion-inneholdende vandig mineralsyre ved værelsetemperatur til moderat forhøyet temperatur og avspalter en forekommende benzyloxycarbonylrest R," ved hydrogenolyse. Som vandig mineralsyre for gjennomføringen av hydrolyseringen egner seg f. eks. 10—84 pst.-ig svovelsyre, videre kan f. eks. også ca 15 pst.-ig til 36 pst.-ig (konsentrert) saltsyre anvendes. Reaksjonstemperaturen velges ved stigende syrekonsentrasjon lavere, ved anvendelse av 84 pst-ig svovelsyre gjennomføres reaksjonen fortrinnsvis ved værelsetemperatur, med 10 pst.-ig svovelsyre eller ca. 1:1 fortynnet saltsyre ved 50—60°. Avspaltningen av en forekommende benzyloxycarbonylrest kan f. eks. finne sted ved behandling with a mercury ion-containing aqueous mineral acid at room temperature to a moderately elevated temperature and cleaves off an occurring benzyloxycarbonyl residue R" by hydrogenolysis. As an aqueous mineral acid for carrying out the hydrolysis, e.g. 10-84% sulfuric acid is suitable, further e.g. e.g. approx. 15% to 36% (concentrated) hydrochloric acid is also used. The reaction temperature is chosen lower when the acid concentration increases, when using 84% sulfuric acid, the reaction is preferably carried out at room temperature, with 10% sulfuric acid or approx. 1:1 diluted hydrochloric acid at 50-60° The cleavage of an occurring benzyloxycarbonyl residue can e.g. take place by treatment

av et tilsvarende mellomprodukt med hydrogen i nærvær av en hydreringskatalysa-tor som f. eks. palladium på kull, i et egnet organisk oppløsningmiddel som f. eks. ethanol. of a corresponding intermediate product with hydrogen in the presence of a hydrogenation catalyst such as e.g. palladium on charcoal, in a suitable organic solvent such as e.g. ethanol.

Enkelte representanter av utgangsstoffene med den generelle formel VII med hydrogen som R2 og R3' er beskrevet i det franske patent 665 M, og er videre eventuelt på den der angitte måte fremstillbare, det vil si ved omsetning av propargylbromid med amalgamert magnesium, sink eller aluminium i en blanding av tetrahydrofuran og toluol og kondensasjon av den oppståtte metallorganiske forbindelse med et tilsvarende definisjonen på R," og R4 substituert 4-piperidon. I stedet for propargylbromid kan også analoge forbindelser som f. eks. 3-brom-l-butin eller l-brom-2-butin anvendes, som gir utgangsstoffer med den generelle formel VII med rest R2 og/eller R3' forskjellig fra hydrogen. Den i det nevnte frariske patent beskrevne fremgangsmåte modifiseres med fordel ved at man i stedet for bare med kvikksølvklorid amalgamert aluminiumpulver anvender slikt som først amalgameres ved hjelp av metallisk kvikksølv og derefter behandles med kvikksølv-klorid. Certain representatives of the starting substances with the general formula VII with hydrogen as R2 and R3' are described in the French patent 665 M, and can also be prepared in the manner indicated there, i.e. by reacting propargyl bromide with amalgamated magnesium, zinc or aluminum in a mixture of tetrahydrofuran and toluene and condensation of the resulting organometallic compound with a corresponding definition of R" and R4 substituted 4-piperidone. Instead of propargyl bromide, analogous compounds such as e.g. 3-bromo-l-butyne or l-bromo-2-butyne is used, which gives starting materials of the general formula VII with residue R2 and/or R3' different from hydrogen. The method described in the aforementioned French patent is advantageously modified by amalgamating instead of just mercury chloride aluminum powder uses that which is first amalgamated with the help of metallic mercury and then treated with mercuric chloride.

Fremstillingen av utgangsstoffer med den generelle formel VII, som inneholder som R," et hydrogenatom kan finne sted f. eks. efter den foran nevnte fremgangsmåte under anvendelse av den dobbelte molare mengde propargylbromid eller en analogt og tilsvarende forhøyet metall-mengde. The production of starting materials with the general formula VII, which contains as R" a hydrogen atom can take place, for example, according to the above-mentioned method using the double molar amount of propargyl bromide or an analogous and correspondingly increased amount of metal.

Ved anvendelse av 1-benzyloxycarbo-nyl-4-piperidon i stedet for 4-piperidon kan det dobbelte forbruk av propargylbromid unngås og ofte et mer ensartet reak-sjonsforløp oppnås, slik at innføringen og til slutt den hydrogenolytiske avspaltning av benzyloxycarbonylgruppen kan lønne seg. By using 1-benzyloxycarbonyl-4-piperidone instead of 4-piperidone, the double consumption of propargyl bromide can be avoided and a more uniform course of reaction is often achieved, so that the introduction and finally the hydrogenolytic cleavage of the benzyloxycarbonyl group can pay off.

Anvender man til spaltning av den fra den metallorganiske omsetning resulteren-de reaksjonsblanding sammen med is i stedet for eddiksyre (sammenlign eksempel 4 i ovenfor nevnte patent) en mineralsyre, f. eks. konsentrert saltsyre, så oppnår man en organisk og en mineralsur vandig fase. Sistnevnte inneholder reaksjonskompo-nentene for fremgangsmåten efter oppfinnelsen, d.v.s. den ønskede forbindelse med den generelle formel VII og kvikksølv-ioner i mineralsur f. eks. saltsur oppløsning og danner, dersom det ved et egnet blan-dingsforhold av is og syre, f. eks. like deler is og konsentrert saltsyre, sørges for en egnet syrekonsentrasjon, allerede utgangs-forbindelsen for fremgangsmåten efter oppfinnelsen, ved hvis oppvarmning slutt-produktet med den generelle formel I oppstår. If a mineral acid, e.g. concentrated hydrochloric acid, then an organic and a mineral acid aqueous phase is obtained. The latter contains the reaction components for the method according to the invention, i.e. the desired compound with the general formula VII and mercury ions in mineral acid e.g. hydrochloric acid solution and forms, if with a suitable mixing ratio of ice and acid, e.g. equal parts ice and concentrated hydrochloric acid, a suitable acid concentration is ensured, already the starting compound for the method according to the invention, upon heating of which the end product with the general formula I is produced.

Tilslutt lar forbindelser med den generelle formel I som oppviser som R, et hydrogenatom og oppnås efter en av de forangående fremgangsmåter, ved omsetning med en reaksjonsdyktig ester av en forbindelse med den generelle formel VIII, Finally, compounds of the general formula I which exhibit as R, a hydrogen atom and are obtained according to one of the preceding methods, by reaction with a reactive ester of a compound of the general formula VIII,

R/-OH VIII R/-OH VIII

hvor R,' har den under den generelle where R,' has it below the general one

formel V angitte betydning, formula V indicated meaning,

seg omvandle til forbindelser med den generelle formel I med R,' i stedet for hydro-genatomet. Omsetningen finner sted f. eks. ved værelsetemperatur eller moderat for-høyet temperatur i et egnet organisk opp-løsningsmiddel som f. eks. ethanol, aceton, ethylacetat eller dimethylformamid. Eventuelt fremskyndes omsetningen ved tilset-ning av syrebindende middel som f. eks. kaliumcarbonat, og/eller kaliumjodid. Som reaksjonsdyktige estere egner seg i særdeleshet halogen-hydrogensyreestere som bromider, klorider og jodider, videre aryl-sulfonsyreester, f. eks. p-toluolsulfonsyre-ester, såvel som lett tilgjengelige svovel - syreestere som dimethylsulfat og diethyl-sulfat. transform into compounds of the general formula I with R,' instead of the hydrogen atom. The turnover takes place e.g. at room temperature or moderately elevated temperature in a suitable organic solvent such as e.g. ethanol, acetone, ethyl acetate or dimethylformamide. If necessary, the turnover is accelerated by the addition of an acid-binding agent such as e.g. potassium carbonate, and/or potassium iodide. As reactive esters, halohydrogen acid esters such as bromides, chlorides and iodides, further aryl sulfonic acid esters, e.g. p-toluenesulfonic acid ester, as well as readily available sulfur - acid esters such as dimethyl sulfate and diethyl sulfate.

Med uorganiske og organiske syrer som saltsyre, bromhydrogensyre, svovelsyre, sal-petersyre, fosforsyre, methansulfonsyre, et-handisulfonsyre, (5-hydroxy-ethansulfon-syre, eddiksyre, propionsyre, maleinsyre, fumarsyre, melkesyre, eplesyre, vinsyre, sit-ronsyre, benzoesyre, salicylsyre, fenyleddik-syre og mandelsyre danner forbindelsene med den generelle formel I salter som er delvis godt vannoppløsehge. With inorganic and organic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, et-handisulfonic acid, (5-hydroxy-ethanesulfonic acid, acetic acid, propionic acid, maleic acid, fumaric acid, lactic acid, malic acid, tartaric acid, citric acid , benzoic acid, salicylic acid, phenylacetic acid and mandelic acid form the compounds of the general formula I salts which are partially water soluble.

De etterfølgende eksempler redegjør for gjennomføringen av fremgangsmåten efter oppfinnelsen. Temperaturene er angitt i Celsiusgrader. The following examples explain the implementation of the method according to the invention. The temperatures are indicated in degrees Celsius.

Eksempel 1. Example 1.

Til en blanding av 226 g l-methyl-4-piperidon og 120 g aceton i 700 ml vann tilsetter man 300 g nøytralt vasket Amberlite IRA 400 (OH~), som på forhånd ble rørt i 15 timer med 2n natronlut ved værelsetemperatur, og rører blandingen i 20 timer ved 30°. Derefter filtreres ioneutveksleren fra og filtratet inndampes på rotasjonsfordamper i vakuum. Resten opptas i kloroformoppløsningen, tørkes med natriumsulfat og inndampes. Råproduktet destilleres i vakuum, hvorved man oppnår To a mixture of 226 g of 1-methyl-4-piperidone and 120 g of acetone in 700 ml of water, 300 g of neutrally washed Amberlite IRA 400 (OH~), which was previously stirred for 15 hours with 2N caustic soda at room temperature, is added, and stirring the mixture for 20 hours at 30°. The ion exchanger is then filtered off and the filtrate is evaporated on a rotary evaporator in vacuum. The residue is taken up in the chloroform solution, dried with sodium sulphate and evaporated. The raw product is distilled in a vacuum, whereby one obtains

1- (l'-methyl-4'-hydroxy-4'-piperidyl)-2-propanon med kpJ0 125—130°. 1-(1'-methyl-4'-hydroxy-4'-piperidyl)-2-propanone with bpJ0 125-130°.

Til omvandling til hydrokloridet opplø-ses den ovenfor nevnte base i en blanding av ether og isopropanol 5:1 og oppløsnin-gen tilsettes med så meget absolutt etherisk saltsyreoppløsning inntil ikke mer hydroklorid faller ut. Hydrokloridet filtreres fra og omkrystalliseres fra isopropanol. Smp. 125—127°. For conversion to the hydrochloride, the above-mentioned base is dissolved in a mixture of ether and isopropanol 5:1 and the solution is added with as much absolute etheric hydrochloric acid solution as possible until no more hydrochloride precipitates. The hydrochloride is filtered off and recrystallized from isopropanol. Temp. 125-127°.

Til fremstilling av citratet oppløses den frie base i aceton og tilsettes under røring sålenge med en mettet oppløsning av cit-ronsyre i aceton inntil oppløsningen rea-gerer surt (pH 4). Det utfelte salt filtreres fra og omkrystalliseres fra aceton/methanol. l-(l'-methyl-4'-hydroxy-4'-piperidyl)-2- propanon-citratet viser et smeltepunkt på 103—105°. To prepare the citrate, the free base is dissolved in acetone and added while stirring with a saturated solution of citric acid in acetone until the solution reacts acidic (pH 4). The precipitated salt is filtered off and recrystallized from acetone/methanol. The 1-(1'-methyl-4'-hydroxy-4'-piperidyl)-2-propanone citrate shows a melting point of 103-105°.

Eksempel 2. Example 2.

Til en blanding av 120 g nøytralt vasket Amberlite IRA 400 (OH~), hvilket på forhånd røres i 15 timer med 2n natronlut ved værelsetemperatur, og 176 g aceton tildryppes under god røring i løpet av 5 timer 67,8 g l-methyl-4-piperidon ved værelsetemperatur og blandingen røres derefter videre i 19 timer. Derefter filtreres ioneutveksleren fra, vaskes med methanol og filtratet inndampes på rotasjonsfordamper i vakuum. Råproduktet destilleres i høyvakuum hvorved man oppnår 1-(1'-methyl-4'-hydroxy-4'-piperidyl)-2-propa-non med kp()()1 75°. (Vedrørende salter sammenlign eksempel 1). To a mixture of 120 g of neutrally washed Amberlite IRA 400 (OH~), which is previously stirred for 15 hours with 2N caustic soda at room temperature, and 176 g of acetone are added dropwise with good stirring over the course of 5 hours, 67.8 g of l-methyl- 4-piperidone at room temperature and the mixture is then stirred further for 19 hours. The ion exchanger is then filtered off, washed with methanol and the filtrate is evaporated on a rotary evaporator in vacuum. The crude product is distilled in a high vacuum whereby 1-(1'-methyl-4'-hydroxy-4'-piperidyl)-2-propanone with bp()()1 75° is obtained. (Regarding salts, compare example 1).

På analog måte fremstilles: l(l'-methyl-4'-hydroxy-4'-piperidyl-2-butanon med kp()0195°, citrat smp. 145—146°; l-(l'-methyl-4'-hydroxy-4'-piperidyl)-2-pentanon, kp,,,,,,.^^—121°, citrat smp. 126— 128°; l-(l'-methyl-4'-hydroxy-4'-piperidyl)-2-hexanon, kp(l0,<1>16—118°; 1- (l'-methyl-4'-hydroxy-4'-piperidyl)-3-methyl-2-butanon, kpo0u-85°, citrat smp. 132—134°; 2- (r-methyl-4'-hydroxy-4'-piperidyl) - cyclohexanon, kpom125°C, smp. 95—96°; 2-(r-methyl-4'-hydroxy-4'-piperidyl)-cyclopentanon, kpft()03115—118°, smp. 70°, citrat smp. 157—158; 1- (l'-methyl-4'-hydroxy-4'-piperidyl)-3-fenyl-2-propanon, kp(l0ft3 <1>32—135°; a-(l'-methyl-4'-hydroxy-4'-piperidyl)-acetofenon, kp(l(Jf 123—125°, hydroklorid smp. 146—147°; 2- (1 '-methyl-4'-hydroxy-4'-piperidyl) -3-pentanon, kponog 95—100°, citrat smp. 130— 132°; l-(l',3'-dimethyl-4'-hydroxy-4'-piperi-dyl)-2-propanon, citrat smp. 120°; l-(r,3'-dimethyl-4'-hydroxy-4'-piperi-dyl)-2-butanon, citrat smp. 140°; 1- (1 '-allyl-4'-hydroxy-4'-piperidyl) -2-butanon, <kp.>0(1l79—83°C, citrat smp. 66— 67°. Prepared in an analogous manner: l(l'-methyl-4'-hydroxy-4'-piperidyl-2-butanone with bp()0195°, citrate m.p. 145-146°; l-(l'-methyl-4' -hydroxy-4'-piperidyl)-2-pentanone, bp,,,,,,.^^—121°, citrate mp 126— 128°; l-(1'-methyl-4'-hydroxy-4' -piperidyl)-2-hexanone, bp(l0,<1>16—118°; 1-(1'-methyl-4'-hydroxy-4'-piperidyl)-3-methyl-2-butanone, kpo0u-85 °, citrate mp 132—134°; 2-(r-methyl-4'-hydroxy-4'-piperidyl)-cyclohexanone, kpom 125°C, mp 95—96°; 2-(r-methyl-4' -hydroxy-4'-piperidyl)-cyclopentanone, kpft()03115—118°, mp 70°, citrate mp 157—158; 1-(1'-methyl-4'-hydroxy-4'-piperidyl)- 3-phenyl-2-propanone, bp(l0ft3 <1>32—135°; a-(1'-methyl-4'-hydroxy-4'-piperidyl)-acetophenone, bp(l(Jf 123—125°, hydrochloride m.p. 146—147°; 2-(1 '-methyl-4'-hydroxy-4'-piperidyl)-3-pentanone, kponog 95—100°, citrate m.p. 130—132°; l-(l' ,3'-dimethyl-4'-hydroxy-4'-piperidyl)-2-propanone, citrate mp 120°;1-(r,3'-dimethyl-4'-hydroxy-4'-piperidyl )-2-butanone, citrate mp 140° 1-(1'-allyl-4'-hydroxy-4'-piperidyl)-2-butane on, <bp.>0(1l79—83°C, citrate m.p. 66— 67°.

Eksempel 3. Example 3.

17,4 g aceton røres med 18,9 g 1-benzyl-4-piperidon og 15 g nøytralt vasket Amberlite IRA 400 (OH-), hvilket på forhånd røres i 15 timer med 2-n natronlut ved værelsetemperatur, i 24 timer ved 50°. Derefter filtreres ioneutveksleren fra og vaskes med methanol og filtratet inndampes på rotasjonsfordamper i vakuum. Resten destilleres i høyvakuum. l-(l'-benzyl-4'-hydr-oxy-4'-piperidyl)-2-propanon koker under 0,01 mm's trykk ved 125°. Det analogt eksempel 1 fremstilte hydroklorid smelter ved 166—168°. 17.4 g of acetone are stirred with 18.9 g of 1-benzyl-4-piperidone and 15 g of neutrally washed Amberlite IRA 400 (OH-), which is previously stirred for 15 hours with 2-N caustic soda at room temperature, for 24 hours at 50°. The ion exchanger is then filtered off and washed with methanol and the filtrate is evaporated on a rotary evaporator in vacuum. The remainder is distilled in high vacuum. 1-(1'-benzyl-4'-hydroxy-4'-piperidyl)-2-propanone boils under 0.01 mm's pressure at 125°. The hydrochloride prepared analogously to example 1 melts at 166-168°.

På analog måte oppnår man under anvendelse av 20,3 g l-(p-fenyl-ethyl)-4-piperidon 1- [1'- (6-f enyl-ethyl) -4'-hydr-oxy-4'-piperidyl] -2-propanonet, hydroklorid smp. 127—129°; og under anvendelse av 14,1 g l-n-propyl-4-piperidon l-(l'-n-propyl-4'-hydroxy-4'-piperidyl)-2-propa-nonet med k<p>(l0180—82°, hydroklorid smp. 137—139°. In an analogous manner, using 20.3 g of 1-(p-phenyl-ethyl)-4-piperidone, 1-[1'-(6-phenyl-ethyl)-4'-hydroxy-4'- piperidyl] -2-propanone, hydrochloride m.p. 127-129°; and using 14.1 g of 1-n-propyl-4-piperidone 1-(1'-n-propyl-4'-hydroxy-4'-piperidyl)-2-propanone with k<p>(l0180-82 °, hydrochloride mp 137-139°.

Eksempel 4. Example 4.

I en kolbe innføres 17,4 g aceton og 20 g Amberlite IR 4B. Derefter tildryppes i løpet av 5 timer 11,3 g l-methyl-4-piperidon under røring og reaksjonsblandingen røres derefter i 19 timer. Ioneutveksleren filtreres fra og vaskes med methanol, filtratet inndampes i vakuum og resten destilleres i vakuum. l-(l'-methyl-4'-hydroxy-4'-piperidyl)-2-propanonet går over under 0,005 mm's trykk ved 80°. Sammenlign eksempel 1. 17.4 g of acetone and 20 g of Amberlite IR 4B are introduced into a flask. 11.3 g of 1-methyl-4-piperidone are then added dropwise over the course of 5 hours with stirring and the reaction mixture is then stirred for 19 hours. The ion exchanger is filtered off and washed with methanol, the filtrate is evaporated in a vacuum and the residue is distilled in a vacuum. The 1-(1'-methyl-4'-hydroxy-4'-piperidyl)-2-propanone converts under 0.005 mm's pressure at 80°. Compare example 1.

Eksempel 5. Example 5.

Til 23,2 g aceton og 20 g Amberlite IRA 400 (OH--form) i 20 ml methanol tildryppes under røring i løpet av 5 timer 11,3 g l-methyl-4-piperidon og blandingen røres derefter videre i 19 timer. Ioneutveksleren filtreres fra og vaskes med methanol. Filtratet inndampes i rotas jonsfordamper og det tilbakeblivende 1-(l'-methyl-4'-hydr-oxy-4'-piperidyl) -2-propanonet destilleres i høyvakuum. Kp0(,m 70—85°, sammenlign eksempel 1. To 23.2 g of acetone and 20 g of Amberlite IRA 400 (OH--form) in 20 ml of methanol, 11.3 g of 1-methyl-4-piperidone is added dropwise with stirring over the course of 5 hours and the mixture is then stirred further for 19 hours. The ion exchanger is filtered off and washed with methanol. The filtrate is evaporated in a rotary evaporator and the remaining 1-(1'-methyl-4'-hydroxy-4'-piperidyl)-2-propanone is distilled in high vacuum. Kp0(,m 70—85°, compare example 1.

Eksempel 6. Example 6.

Til 11,3 g l-methyl-4-piperidon og 5,8 g aceton tilsettes under røring 0,10 g natri- To 11.3 g of 1-methyl-4-piperidone and 5.8 g of acetone, 0.10 g of sodium

ummethylat, hvorved reaksjonsblandingen oppvarmer seg til 40°. Efter 8 timers henstand ved værelsetemperatur oppløses den nå tykt flytende reaksjonsblanding i 80 ml kloroform og oppløsningen ekstraheres med lite vann, såvel som to ganger med mettet natriumkloridoppløsning. Derefter tørkes kloroformoppløsningen med natriumsulfat og inndampes og resten destilleres i høy-vakuum, hvorved l-(l'-methyl-4'-hydroxy-4'-piperidyl)-2-propanonet med kp()ll-80° oppnås, sammenlign eksempel 1. ummethylate, whereby the reaction mixture heats up to 40°. After standing for 8 hours at room temperature, the now thick liquid reaction mixture is dissolved in 80 ml of chloroform and the solution is extracted with a little water, as well as twice with saturated sodium chloride solution. The chloroform solution is then dried with sodium sulfate and evaporated and the residue is distilled in high vacuum, whereby the 1-(1'-methyl-4'-hydroxy-4'-piperidyl)-2-propanone with bp()11-80° is obtained, compare example 1.

Eksempel 7. Example 7.

Til en oppløsning av 7,2 g aceton i 50 ml 2-n natronlut tildryppes i løpet av 5 timer 11,3 g l-metbyl-4-piperidon. Man rører blandingen' ytterligere 24 timer, trek-ker den så ut med kloroform, tørker kloro-formoppløsningen med natriumsulfat og inndamper den. Ved destillasjon av resten oppnår man l-(l'-methyl-4'-hydroxy-4'-piperidyl)-2-propanonet med kp001<7>0—85°, sammenlign eksempel 1. To a solution of 7.2 g of acetone in 50 ml of 2-n caustic soda, 11.3 g of 1-methbyl-4-piperidone is added dropwise over the course of 5 hours. The mixture is stirred for a further 24 hours, then extracted with chloroform, the chloroform solution is dried with sodium sulphate and evaporated. Distillation of the residue gives 1-(1'-methyl-4'-hydroxy-4'-piperidyl)-2-propanone with bp001<7>0-85°, compare example 1.

Eksempel 8. Example 8.

a) Til en blanding av 29,2 g benzyliden-aceton og 20 g Amberlite IRA 400 (OH--form, forbehandlet som i forangående eksempler) i 60 ml methanol tildryppes ved 40—50° 11,3 g l-methyl-4-piperidon i løpet av 4 timer og derefter røres reaksjonsblandingen ennu 15 timer ved 40—50°. Ioneutveksleren filtreres fra, vaskes med methanol og filtratet inndampes på rotas jonsfordamper. Ved destillasjonen av resten i høy-vakuum går l-(l'-methyl-4'-hydroxy-4'-piperidyl) -3-benzyliden-2-propanonet under 0,01 torr over ved 131—155°. Det analogt de forangående eksempler fremstilte citrat smelter ved 165—167°. b) På analog måte oppnår man ved å gå ut fra 11,3 g l-methyl-4-piperidon og 22,4 a) To a mixture of 29.2 g of benzylidene acetone and 20 g of Amberlite IRA 400 (OH--form, pretreated as in previous examples) in 60 ml of methanol, at 40-50°, 11.3 g of l-methyl-4 -piperidone during 4 hours and then the reaction mixture is stirred for another 15 hours at 40-50°. The ion exchanger is filtered off, washed with methanol and the filtrate is evaporated on a rotary ion evaporator. During the distillation of the residue in high vacuum, the 1-(1'-methyl-4'-hydroxy-4'-piperidyl)-3-benzylidene-2-propanone undergoes below 0.01 torr at 131-155°. The citrate produced analogously to the previous examples melts at 165-167°. b) In an analogous way, starting from 11.3 g of l-methyl-4-piperidone and 22.4

g 2-methyl-cyclohexanon 2-(l'-methyl-4'-hydroxy-4'-piperidyl)-6-methyl-cyclohexanon, kpnon2119-127°, smp. 125—126°. g 2-methyl-cyclohexanone 2-(1'-methyl-4'-hydroxy-4'-piperidyl)-6-methyl-cyclohexanone, kpnon2119-127°, m.p. 125-126°.

Eksempel 9. Example 9.

11,3 g l-methyl-4-piperidon tildryppes til en blanding av 21,6 g 2-butanon og 30 g Amberlite IR 120 (H+<->form) i 60 ml vann i løpet av 3 timer ved 60° under røring. Derefter røres blandingen i 13 timer ved 60°. Efter filtrering og inndampning av filtratet blir en olje tilbake, som ved destillasjon i høyvakuum gir l-(l'-methyl-4'-hydroxy-4'-piperidyl)-2-butanon med kp0 005 80—83°. 11.3 g of 1-methyl-4-piperidone is added dropwise to a mixture of 21.6 g of 2-butanone and 30 g of Amberlite IR 120 (H+<->form) in 60 ml of water over the course of 3 hours at 60° with stirring . The mixture is then stirred for 13 hours at 60°. After filtration and evaporation of the filtrate, an oil remains, which on distillation in high vacuum yields 1-(1'-methyl-4'-hydroxy-4'-piperidyl)-2-butanone with bp0 005 80-83°.

Det derav fremstilte citrat smelter ved 145—146°, sammenlign eksempel 2. The resulting citrate melts at 145-146°, compare example 2.

Eksempel 10. Example 10.

a) 120 g acetofenon oppvarmes med 99 g cyclohexylamin i 300 ml abs. toluol i 20 a) 120 g acetophenone is heated with 99 g cyclohexylamine in 300 ml abs. toluene in 20

timer i vannavskiller. Den gule reaksjons-oppløsning inndampes og resten destilleres under høyvakuum, hvorved den Schiffske base, acetofenon-N-cyclohexyl-iminet med kponm90—91° oppnås. hours in water separators. The yellow reaction solution is evaporated and the residue is distilled under high vacuum, whereby the Schiff base, acetophenone-N-cyclohexyl imine with kponm90-91° is obtained.

b) I en trehalskolbe innføres under nitro-gen 0,6 g litium i 100 ml abs. ether og under b) In a three-necked flask, under nitrogen, introduce 0.6 g of lithium in 100 ml of abs. ether and below

røring tildryppes ca. en tredjedel av opp-løsningen av 6,75 g brombenzol i 50 ml abs. ether. Ved oppvarmning ved hjelp av et vannbad bringes reaksjonen i gang og derefter tildryppes resten av brombenzolet. Derefter kokes den mørke brune oppløsning 30 minutter under tilbakeløp. Den erholdte fenyl-litiumoppløsning omhelles i en annen firehalskolbe og avkjøles til -^10°. Under røring tildryppes 4,35 g diisopropylamin i 5 ml abs. ether i løpet av 15 minutter, hvorved en grønnlig suspensjon danner seg. Efter ytterligere 10 minutter tildryppes 8,5 g av den efter a) erholdte Schiffske base i 10 ml abs. ether ved 0° og det hele røres videre i 15 minutter. Derefter tildryppes 4,8 g l-methyl-4-piperidon i 5 ml abs. ether og blandingen røres videre i 15 timer. Derefter spaltes den med vann, fasen skilles fra og den etheriske fasen vaskes med vann, tørkes og inndampes. Krystallgrøten røres med ether og filtreres. Det erholdte oj-(1-methyl-4-hydroxy-4-piperidyl)-acetofenon-N-cyclohexyl-imin smelter ved 110 stir in approx. one third of the solution of 6.75 g of bromobenzene in 50 ml of abs. ether. By heating using a water bath, the reaction is started and then the remainder of the bromobenzene is added dropwise. The dark brown solution is then boiled for 30 minutes under reflux. The phenyllithium solution obtained is decanted into another four-necked flask and cooled to -^10°. While stirring, 4.35 g of diisopropylamine are added dropwise in 5 ml of abs. ether during 15 minutes, whereby a greenish suspension forms. After a further 10 minutes, 8.5 g of the Schiffske base obtained after a) are added dropwise in 10 ml abs. ether at 0° and the whole is stirred further for 15 minutes. Then 4.8 g of 1-methyl-4-piperidone are added dropwise in 5 ml of abs. ether and the mixture is further stirred for 15 hours. It is then split with water, the phase is separated and the ethereal phase is washed with water, dried and evaporated. The crystal slurry is stirred with ether and filtered. The obtained oj-(1-methyl-4-hydroxy-4-piperidyl)-acetophenone-N-cyclohexyl-imine melts at 110

—111°. c) 0,5 g av produktet efter b) oppvarmes med 5 ml 2-n. svovelsyre i 3 timer ved 60°. -111°. c) 0.5 g of the product from b) is heated with 5 ml of 2-n. sulfuric acid for 3 hours at 60°.

Derefter innstilles reaksjonsblandingen alkalisk og trekkes ut med kloroform, tørkes og inndampes. Ved destillasjon i høyva-kuum oppnår man rø-(r-methyl-4'-hydr-oxy-4-piperidyl)-acetofenonet hvis hydrokloridet smelter ved 146—147°, sammenlign eksempel 2. The reaction mixture is then made alkaline and extracted with chloroform, dried and evaporated. Distillation in high vacuum gives the red-(r-methyl-4'-hydroxy-4-piperidyl)-acetophenone if the hydrochloride melts at 146-147°, compare example 2.

Eksempel 11. Example 11.

a) 4,05 g aluminiumpulver tilsettes 10 g kvikksølv og blandes godt med en rører. a) 4.05 g of aluminum powder is added to 10 g of mercury and mixed well with a stirrer.

Derefter avdekanteres det uoppbrukte kvikksølv. Det amalgamerte aluminium i 25 ml abs. tetrahydrofuran og 15 ml abs. benzol oppkokes kort med 15 mg kvikksølv-klorid og røres derefter videre i 15 minutter. Derefter tilsettes ved 50—60° av totalt 20,5 ml propargylbromid så meget uten oppløsningsmiddel inntil reaksjonen kom- The unused mercury is then decanted off. The amalgamated aluminum in 25 ml abs. tetrahydrofuran and 15 ml abs. benzol is boiled briefly with 15 mg of mercuric chloride and then stirred further for 15 minutes. Then, at 50-60°, a total of 20.5 ml of propargyl bromide is added as much without solvent until the reaction comes

mer igang og temperaturen stiger mot 70°; more activity and the temperature rises towards 70°;

derefter tilføyes det resterende propargylbromid, fortynnet med 35 abs. benzol. Blandingen røres i 30 minutter. Derefter tildryppes langsomt ved 20—25° 50 g 1-(|3-fenyl-ethyl)-4-piperidon i 150 ml absolutt benzol under isavkjølning og blandingen røres videre i 15 timer. Derefter spaltes den med is og 2-n saltsyre, den vandige fase skilles fra, vaskes med kloroform og innstilles alkalisk med konsentrert natronlut, og den frisatte base opptas i kloroform. Kloroformoppløsningen tørkes og inndampes og resten destilleres, hvorved l-((3-fenyl-ethyl)-4-(2'-propinyl)-4-piperidinol med kp(1 M 130—140° oppnås. then add the remaining propargyl bromide, diluted with 35 abs. benzene. The mixture is stirred for 30 minutes. Then, at 20-25°, 50 g of 1-(|3-phenyl-ethyl)-4-piperidone are slowly added dropwise in 150 ml of absolute benzene under ice-cooling and the mixture is further stirred for 15 hours. It is then split with ice and 2-n hydrochloric acid, the aqueous phase is separated, washed with chloroform and made alkaline with concentrated caustic soda, and the released base is taken up in chloroform. The chloroform solution is dried and evaporated and the residue is distilled, whereby 1-((3-phenyl-ethyl)-4-(2'-propynyl)-4-piperidinol with bp (1 M 130-140°) is obtained.

På analog måte oppnår man f. eks.: l-benzyl-4-(2'-propinyl)-4-piperidinol, kpno;j 128—135°; l-methyl-4-(2'-propinyl)-4-piperidinol, smp. 91—93°; l-methyl-4-(l'-methyl-2'-propinyl)-4-piperidinol, kpo f)l 75—78°; l-ethyl-4-(2'-propinyl)-4-piperidinol, l-n-butyl-4- (2'-propinyl) -4-piperidinol, l-n-dodecyl-4- (2'-propinyl) -4-piperidinol, 1- (a-methyl-p-fenyl-ethyl)-4- (2'-propinyl) -4-piperidinol, l-(Y-fenyl-propyl)-4-(2'-propinyl)-4-piperidinol. In an analogous manner one obtains, for example: 1-benzyl-4-(2'-propynyl)-4-piperidinol, mp 128-135°; 1-methyl-4-(2'-propynyl)-4-piperidinol, m.p. 91-93°; 1-methyl-4-(1'-methyl-2'-propynyl)-4-piperidinol, kpo f)1 75-78°; l-ethyl-4-(2'-propynyl)-4-piperidinol, l-n-butyl-4-(2'-propynyl)-4-piperidinol, l-n-dodecyl-4-(2'-propynyl)-4-piperidinol , 1-(α-methyl-p-phenyl-ethyl)-4-(2'-propynyl)-4-piperidinol, 1-(Y-phenyl-propyl)-4-(2'-propynyl)-4-piperidinol .

b) 5,3 g l-((3-fenyl-ethyl)-4-(2'-propinyl)-4-piperidinol røres med 21 ml 10 pst.-ig b) 5.3 g of 1-((3-phenyl-ethyl)-4-(2'-propynyl)-4-piperidinol is stirred with 21 ml of 10%

svovelsyre og 300 mg kvikksølvsulfat i 5 timer ved 60°. Derefter innstilles blandingen alkalisk med konsentrert natronlut og ekstraheres med kloroform. Kloroformopp-løsningen vaskes med mettet natriumklo-ridoppløsning, tørkes og inndampes. Destillasjon av resten gir l-[l'-(p-fenyl-ethyl)-4'-hydroxy-4'-piperidyl] -2-propanonet med kpom 135—140°. sulfuric acid and 300 mg of mercuric sulphate for 5 hours at 60°. The mixture is then made alkaline with concentrated caustic soda and extracted with chloroform. The chloroform solution is washed with saturated sodium chloride solution, dried and evaporated. Distillation of the residue gives the 1-[1'-(p-phenyl-ethyl)-4'-hydroxy-4'-piperidyl]-2-propanone with kpom 135-140°.

Det fra en oppløsning av basen isopropanol/ether ved hjelp av etherisk salt-syreoppløsning utfelte hydroklorid smelter efter omkrystallisasjon fra isopropanol ved 127—129°, sammenlign eksempel 3. The hydrochloride precipitated from a solution of the base isopropanol/ether by means of an ethereal hydrochloric acid solution melts after recrystallization from isopropanol at 127-129°, compare example 3.

På analog måte oppnås f. eks.: l-(l'-benzyl-4'-hydroxy-4'-piperidyl)-2-propanon, kpn 0I 130—135°, hydroklorid smp. 166—168°, sammenlign eksempel 3. l-(l'-methyl-4'-hydroxy-4'-piperidyl)-2-propanon, kpn ni 75°, kp12 125—130°, hydroklorid smp. 125—127° (fra isopropanol), citrat smp. 103—105°, sammenlign eksempel 1; 3-(r-methyl-4'-hydroxy-4'-piperidyl)-2-butanon, kp()0)78—80°; citrat smp. 125— 126°; l-(l'-ethyl-4'-hydroxy-4'-piperidyl)-2-propanon; 1 - (1 '-n-butyl-4'-hydi'oxy-4'-piperidyl) - 2-propanon; 1- (r-n-dodecyl-4'-hydroxy-4'-piperidyl)-2- propanon, kp00!)135—138°; 1- [1'- (a-methyl-p-f enyl-ethyl) -4'-hydr-oxy-4'-piperidyl]-2-propanon; 1 - [1'- ( y- ienyl-propyl) -4'-hydroxy-4'-piperidyl] -2-propanon. In an analogous manner is obtained, for example: 1-(1'-benzyl-4'-hydroxy-4'-piperidyl)-2-propanone, bp 01 130-135°, hydrochloride m.p. 166—168°, compare example 3. 1-(1'-methyl-4'-hydroxy-4'-piperidyl)-2-propanone, bp ni 75°, bp12 125—130°, hydrochloride m.p. 125—127° (from isopropanol), citrate m.p. 103—105°, compare example 1; 3-(r-methyl-4'-hydroxy-4'-piperidyl)-2-butanone, bp(0)78-80°; citrate m.p. 125— 126°; 1-(1'-ethyl-4'-hydroxy-4'-piperidyl)-2-propanone; 1-(1'-n-butyl-4'-hydroxy-4'-piperidyl)-2-propanone; 1-(r-n-dodecyl-4'-hydroxy-4'-piperidyl)-2-propanone, bp00!)135-138°; 1-[1'-(α-methyl-p-phenylethyl)-4'-hydroxy-4'-piperidyl]-2-propanone; 1 - [1'-(γ-ienyl-propyl)-4'-hydroxy-4'-piperidyl]-2-propanone.

Eksempel- 12. Example- 12.

a) 4,05 g aluminiumpulver tilsettes 10 g kvikksølv og blandes godt med en rører. a) 4.05 g of aluminum powder is added to 10 g of mercury and mixed well with a stirrer.

Derefter avdekanteres det uoppbrukte kvikksølv. Det amalgamerte aluminium i 25 ml abs. tetrahydrofuran og 15 ml abs. benzol kokes kort opp med 15 mg kvikk-sølvklorid og røres derefter videre i 15 minutter. Derefter tilsettes ved 50—60° av totalt 20,5 ml propargylbromid så meget uten oppløsningsmiddel inntil reaksjonen kommer igang og temperaturen stiger mot 70°; derefter tilføyes det resterende propargylbromid fortynnet med 35 abs. benzol. Blandingen røres i 30 minutter. Derefter tildryppes ved 20—25° 50 g l-(p-fenyl-ethyl)-4-piperidon i 150 ml abs. benzol under isavkjøling og blandingen røres ytterligere i 15 timer. Derefter spaltes reaksjonsblandingen med ca. 150 g is og 150 ml konsentrert saltsyre og benzolfasen skilles fra. The unused mercury is then decanted off. The amalgamated aluminum in 25 ml abs. tetrahydrofuran and 15 ml abs. benzol is briefly boiled with 15 mg of mercuric chloride and then stirred further for 15 minutes. Then, at 50-60°, a total of 20.5 ml of propargyl bromide is added as much without solvent until the reaction starts and the temperature rises towards 70°; then the remaining propargyl bromide diluted with 35 abs. benzene. The mixture is stirred for 30 minutes. Then, at 20-25°, 50 g of 1-(p-phenyl-ethyl)-4-piperidone are added dropwise in 150 ml of abs. benzene under ice-cooling and the mixture is further stirred for 15 hours. The reaction mixture is then split with approx. 150 g of ice and 150 ml of concentrated hydrochloric acid and the benzene phase is separated.

b) Den erholdte saltsure oppløsning røres i 4—6 timer ved 40—60°. Derefter vaskes b) The obtained hydrochloric acid solution is stirred for 4-6 hours at 40-60°. Then wash

den med kloroform, innstilles alkalisk med konsentrert natronlut og ekstraheres med kloroform. Kloroformoppløsningen tørkes og inndampes og resten destilleres, hvorved 1- [1'- (p-fenyl-ethyl)-4'-hydroxy-4'-piperidyl]-2-propanonet med kpft(li 135— 140° oppnås, sammenlign eksemplene 3 og 11. that with chloroform, made alkaline with concentrated caustic soda and extracted with chloroform. The chloroform solution is dried and evaporated and the residue is distilled, whereby the 1-[1'-(p-phenyl-ethyl)-4'-hydroxy-4'-piperidyl]-2-propanone with kpft(li 135— 140° is obtained, compare examples 3 and 11.

Analogt til arbeidsmåten i eksempel 12 eller 11 kan f. eks. også følgende forbindelser oppnås (sammenlign dertil også eksempel 2): 1- (1 '-methyl-4'-hydroxy-4'-piperidyl) -2-butanon, kpno, 95°, citrat smp. 145—146°; l-(l'-methyl-4'-hydroxy-4'-piperidyl)-2-pentanon, kp,,^., 119—121°, citrat smp. 126—128°; l-(r-methyl-4'-hydroxy-4'-piperidyl)-2-hexanon, kp0,„ 116—118°; 1- (l'-methyl-4'-hydroxy-4'-piperidyl)-3-fenyl-2-propanon, kpn0l)., <1>32—135°; 2- (<r->methyl-4'-hydroxy-4'-piperidyl)-3-pentanon, kp() 008 9 5—100°, citrat 130—132°; 1- (l'-n-propyl-4'-hydroxy-4'-piperidyl)-2- propanon, kp0 ,„ 80—82°, hydroklorid smp. 137—139°. Analogous to the way of working in example 12 or 11, e.g. also the following compounds are obtained (compare thereto also example 2): 1-(1'-methyl-4'-hydroxy-4'-piperidyl)-2-butanone, kpno, 95°, citrate m.p. 145-146°; 1-(1'-methyl-4'-hydroxy-4'-piperidyl)-2-pentanone, bp,,^., 119—121°, citrate m.p. 126—128°; 1-(r-methyl-4'-hydroxy-4'-piperidyl)-2-hexanone, bp0,„ 116-118°; 1-(1'-methyl-4'-hydroxy-4'-piperidyl)-3-phenyl-2-propanone, bpn01)., <1>32—135°; 2- (<r->methyl-4'-hydroxy-4'-piperidyl)-3-pentanone, bp() 008 9 5—100°, citrate 130—132°; 1-(1'-n-propyl-4'-hydroxy-4'-piperidyl)-2-propanone, bp0 ,„ 80—82°, hydrochloride m.p. 137-139°.

Eksempel 13. Example 13.

a) 12 g fint pulverisert hydroklorid av 4-piperidinol tilsettes til 20 g fint pulverisert a) 12 g of finely powdered hydrochloride of 4-piperidinol is added to 20 g of finely powdered

natriumhydroxyd i 80 ml kloroform ved -^20°. Derefter tilsettes langsomt 2 ml vann, hvorpå temperaturen stiger. Det sør-ges derfor for kjøling slik at den ikke stiger over 10°. Derefter tilsettes natriumsulfat, reaksjonsblandingen filtreres og filtratet inndampes i rotas jonsfordamper, til sist under høyvakuum i 5 minutter, hvorved 4-piperidinolet blir tilbake. 9 g magnesium i 30 ml abs. ether innføres, 0,1 g kvikksølvklorid tilsettes og ved -4-10° til — 5° tildryppes 44,5 g propargylbromid i 100 ml abs. ether. Derefter røres det videre ennu 20 minutter ved -4-5°. Ved -4-5—0° tildryppes derefter 28,95 g 4-piperidinol i 250 ml abs. benzol, hvorved reaksjonsblandingen oppvarmer seg. Det røres videre i 30 minutter ved 0° og derefter ca. 14 timer ved værelsetemperatur. Derefter tilsetter man is og iseddik, skiller fra benzolfasen og ekstraherer den med 2-n eddiksyre. De eddiksure oppløsninger forenes, rystes med ether og innstilles derefter alkalisk. Den frisatte base ekstraheres med kloroform, kloroformoppløsningen tørkes og inndampes, hvorved 9,3 g av en olje blir tilbake. Destillasjonen gir en olje med kp^.-100— sodium hydroxide in 80 ml of chloroform at -^20°. Then slowly add 2 ml of water, after which the temperature rises. Cooling is therefore ensured so that it does not rise above 10°. Sodium sulphate is then added, the reaction mixture is filtered and the filtrate is evaporated in a rotary evaporator, finally under high vacuum for 5 minutes, whereby the 4-piperidinol is returned. 9 g magnesium in 30 ml abs. ether is introduced, 0.1 g of mercuric chloride is added and at -4-10° to — 5° 44.5 g of propargyl bromide are added dropwise in 100 ml abs. ether. It is then stirred for another 20 minutes at -4-5°. At -4-5-0°, 28.95 g of 4-piperidinol are then added dropwise in 250 ml abs. benzene, whereby the reaction mixture heats up. It is stirred further for 30 minutes at 0° and then approx. 14 hours at room temperature. Ice and glacial acetic acid are then added, separated from the benzene phase and extracted with 2-n acetic acid. The acetic acid solutions are combined, shaken with ether and then made alkaline. The liberated base is extracted with chloroform, the chloroform solution is dried and evaporated, leaving 9.3 g of an oil. The distillation gives an oil with kp^.-100—

140° (luftbad), som krystalliserer. Det således erholdte 4-(2'-propinyl)-4-piperidinol smelter ved 76—78°. 140° (air bath), which crystallizes. The 4-(2'-propynyl)-4-piperidinol thus obtained melts at 76-78°.

b) 1,6 g av produktet fra a) står til henstand med 16 ml 2-n. svovelsyre og 200 mg b) 1.6 g of the product from a) is prepared with 16 ml of 2-n. sulfuric acid and 200 mg

kvikksølvsulfat i 3 timer ved værelsetemperatur. Reaksjonsblandingen innstilles alkalisk og trekkes ut med kloroform. Klo-roformoppløsningen tørkes og inndampes. mercury sulfate for 3 hours at room temperature. The reaction mixture is made alkaline and extracted with chloroform. The chloroform solution is dried and evaporated.

Resten destilleres i kulerør, hvorved l-(4'-hydroxy-4'-piperidyl)-2-propanonet oppnås, kpn o, 70°, smp. 98—100°. The residue is distilled in a ball tube, whereby the 1-(4'-hydroxy-4'-piperidyl)-2-propanone is obtained, bp o, 70°, m.p. 98—100°.

Eksempel 14. Example 14.

a) I en egnet kolbe oppløses 15,35 g 4-piperidon-hydrathydroklorid i 110 ml l-n a) In a suitable flask, dissolve 15.35 g of 4-piperidone hydrate hydrochloride in 110 ml l-n

natriumbicarbonatoppløsning. Under kjøl-ning og vibrering tildryppes ved 5—10° 17,1 g benzyloxycarbonylklorid og 110 ml l-n natriumbicarbonatoppløsning således at reaksjonsblandingen stadig forblir alkalisk. Derefter vibreres det videre i iy2 time og den oppståtte melkeaktige emulsjon trekkes ut med ether. Etheroppløsningen gjennomrystes 2 ganger med 2n saltsyre og derefter 2 ganger med mettet natriumklorid-oppløsning, tørkes og inndampes og resten destilleres i høyvakuum. 1-benzyl-oxycar-bonyl-4-piperidon koker ved 125—131°/ 0,004 torr. sodium bicarbonate solution. During cooling and shaking, at 5-10°, 17.1 g of benzyloxycarbonyl chloride and 110 ml of 1-1 sodium bicarbonate solution are added dropwise so that the reaction mixture remains always alkaline. It is then vibrated further for iy2 hours and the resulting milky emulsion is extracted with ether. The ether solution is shaken twice with 2N hydrochloric acid and then twice with saturated sodium chloride solution, dried and evaporated and the residue distilled under high vacuum. 1-benzyl-oxycarbonyl-4-piperidone boils at 125-131°/ 0.004 torr.

b) I en rørekolbe innføres 4 g magnesium i 6 ml abs. ether og derefter tildryppes under b) In a stirring flask, introduce 4 g of magnesium in 6 ml of abs. ether and then added dropwise below

røring mellom 10—15° 19,5 g propargylbromid i 35 ml abs. ether. Derefter tildryppes langsomt 19,1 g 1-benzyloxycarbonyl-4-piperidon i 80 ml abs. benzol ved 20—25°, hvorved en klump danner seg, som løser seg igjen ved videre røring. Derefter røres reaksjonsblandingen i ytterligere 3 timer. Derefter spaltes den med is og 2n svovelsyre og trekkes ut med ether. Etheropp-løsningen gjennomrystes godt med 2n svovelsyre, tørkes og inndampes. Det tilbakeblivende l-benzyloxycarbonyl-4- (2'-propinyl)-4-piperidinol koker ved 160—163°/0,01 torr. stirring between 10—15° 19.5 g propargyl bromide in 35 ml abs. ether. 19.1 g of 1-benzyloxycarbonyl-4-piperidone are then slowly added dropwise in 80 ml of abs. benzol at 20—25°, whereby a lump forms, which dissolves again on further stirring. The reaction mixture is then stirred for a further 3 hours. It is then decomposed with ice and 2N sulfuric acid and extracted with ether. The ether solution is shaken well with 2N sulfuric acid, dried and evaporated. The remaining 1-benzyloxycarbonyl-4-(2'-propynyl)-4-piperidinol boils at 160-163°/0.01 torr.

c) 50 g l-benzyloxyearbonyl-4-(2'-propinyl)-4-piperidinol oppvarmes i en blanding c) 50 g of 1-benzyloxycarbonyl-4-(2'-propynyl)-4-piperidinol are heated in a mixture

av 500 ml 20 pst.-ig svovelsyre og 350 ml dioxan, som inneholder 5 g kvikksølvsul-fat, 1 time ved 35—40°. Derefter avdampes dioxanet i vakuum, resten trekkes ut med kloroform, kloroformekstraktet vaskes med mettet natriumkloridoppløsning, tørkes og inndampes. Ved destillasjon av resten oppnår man l-(l'-benzyloxycarbonyl-4'-hydr-oxy-4'-piperidyl)-2-propanonet med kp0(ri 180—190°. of 500 ml of 20% sulfuric acid and 350 ml of dioxane, which contains 5 g of mercury sulphate, for 1 hour at 35-40°. The dioxane is then evaporated in vacuo, the residue is extracted with chloroform, the chloroform extract is washed with saturated sodium chloride solution, dried and evaporated. Distillation of the residue gives 1-(1'-benzyloxycarbonyl-4'-hydroxy-4'-piperidyl)-2-propanone with bp0(ri 180-190°.

d) 30,8 g l-(l'-benzyloxycarbonyl-4'-hydr-oxy-4'-piperidyl)-2-propanon oppløses i d) 30.8 g of 1-(1'-benzyloxycarbonyl-4'-hydroxy-4'-piperidyl)-2-propanone is dissolved in

350 ml methanol og i nærvær av 3 g og senere ytterligere 1,5 g 5 pst.-ig palladium-kull gjennomledes hydrogen, inntil intet karbondioxyd mer kan påvises (ca. 5 timer). Derefter filtreres katalysatoren fra, oppløsningen inndampes, resten tas opp i methylenklorid, oppløsningen tørkes og inndampes og resten destilleres i høyva-kuum. l-(4'-hydroxy-4'-piperidyl)-2-pro-panonet går ved 0,01 torr over ved 80— 100° luftbadtemperatur under delvis spaltning, smeltepunkt 98—100°, sammenlign eksempel 13. 350 ml of methanol and, in the presence of 3 g and later a further 1.5 g of 5% palladium charcoal, hydrogen is passed through, until no more carbon dioxide can be detected (approx. 5 hours). The catalyst is then filtered off, the solution is evaporated, the residue is taken up in methylene chloride, the solution is dried and evaporated and the residue is distilled under high vacuum. The 1-(4'-hydroxy-4'-piperidyl)-2-propanone passes at 0.01 torr at 80—100° air bath temperature with partial decomposition, melting point 98—100°, compare Example 13.

Eksempel 15. Example 15.

9,3 g rå 4-(2'-propinyl) -4-piperidinol, oppnådd ifølge eksempel 13 a), står til henstand med 50 ml 2-n. svovelsyre og 0,5 9.3 g of crude 4-(2'-propynyl)-4-piperidinol, obtained according to example 13 a), is left to rest with 50 ml of 2-n. sulfuric acid and 0.5

g kvikksølv-II-sulfat 15 timer ved værelsetemperatur. Derefter innstilles reaksjonsblandingen alkalisk med natronlut og trekkes ut med kloroform. Kloroformoppløs-ningen tørkes og inndampes. Resten på 4,1 g mercury-II-sulphate 15 hours at room temperature. The reaction mixture is then made alkaline with caustic soda and extracted with chloroform. The chloroform solution is dried and evaporated. The rest of 4.1

g oppløses i 20 ml methanol, tilsettes 10 g benzylbromid og står til henstand 48 timer ved 20°. Derefter inndampes blandingen under vakuum, vann tilsettes og den surt reagerende oppløsning rystes med ether. Den vandige fase innstilles alkalisk, og trekkes ut med kloroform, kloroformopp- g is dissolved in 20 ml of methanol, 10 g of benzyl bromide is added and allowed to stand for 48 hours at 20°. The mixture is then evaporated under vacuum, water is added and the acid-reacting solution is shaken with ether. The aqueous phase is made alkaline, and extracted with chloroform, chloroform

løsningen tørkes og inndampes og resten destilleres i høyvakuum. l-(l'-benzyl-4'-hydroxy-4'-piperidyl) -2-propanonet koker i kulerør under 0,01 torr ved 115—125°. Hydrokloridet smelter ved 166—168°, sammenlign eksemplene 3 og 11. b) På analog måte oppnås under anvendelse av 8 g methyljodid istedetfor benzylbromid 1- (l'-methyl-4'-hydroxy-4'-piperi-dyl)-2-propanonet, smeltepunkt for citratet 103—105°, sammenlign eksemplene 1 og 11. the solution is dried and evaporated and the residue is distilled under high vacuum. The 1-(1'-benzyl-4'-hydroxy-4'-piperidyl)-2-propanone boils in bubble tubes below 0.01 torr at 115-125°. The hydrochloride melts at 166-168°, compare examples 3 and 11. b) In an analogous way, using 8 g of methyl iodide instead of benzyl bromide, 1-(1'-methyl-4'-hydroxy-4'-piperidyl)-2 is obtained -the propanone, melting point of the citrate 103—105°, compare examples 1 and 11.

Eksempel 16. Example 16.

1 g l-(4'-hydroxy-4'-piperidyl)-2-pro-panon (sammenlign eksemplene 13 og 14) oppløst i 5 ml ethanol tilsettes 3 ml allyl-bromid og står til henstand 24 timer. Derefter inndampes reaksjonsblandingen, resten oppløst i 2-n. saltsyre, rystes med ether, den vandige fase innstilles alkalisk og trekkes ut med kloroform. Kloroformoppløsnin-gen tørkes, inndampes og resten destilleres i høyvakuum. l-(l'-allyl-4'-hydroxy-4'-piperidyl)-2-propanonet går ved 0,01 torr over ved 105—125° luftbadtemperatur, smp. for citratet 75—78°. 1 g of 1-(4'-hydroxy-4'-piperidyl)-2-propanone (compare examples 13 and 14) dissolved in 5 ml of ethanol is added to 3 ml of allyl bromide and allowed to stand for 24 hours. The reaction mixture is then evaporated, the residue dissolved in 2-n. hydrochloric acid, shaken with ether, the aqueous phase made alkaline and extracted with chloroform. The chloroform solution is dried, evaporated and the residue is distilled under high vacuum. The l-(l'-allyl-4'-hydroxy-4'-piperidyl)-2-propanone undergoes at 0.01 torr at 105-125° air bath temperature, m.p. for the citrate 75-78°.

Eksempel 17. Example 17.

2 g 1-(4'-hydroxy-4'-piperidyl)-2-pro-panon (sammenlign eksemplene 13 og 14) kokes med 4 g n-hexylbromid, 1 g kaliumjodid og 1 g kaliumcarbonat i 25 ml aceton i 4 timer under tilbakeløp. Derefter inndampes reaksjonsblandingen, tilsettes lite vann og den alkaliske oppløsning ekstraheres med kloroform. Kloroformoppløsnin-gen tørkes, inndampes i vakuum og resten destilleres i høyvakuum, hvorved l-(l'-n-hexyl-4'-hydroxy-4'-piperidyl)-2-propa-nonet med kpn 0o3 98° oppnås. 2 g of 1-(4'-hydroxy-4'-piperidyl)-2-propanone (compare examples 13 and 14) are boiled with 4 g of n-hexyl bromide, 1 g of potassium iodide and 1 g of potassium carbonate in 25 ml of acetone for 4 hours during reflux. The reaction mixture is then evaporated, a little water is added and the alkaline solution is extracted with chloroform. The chloroform solution is dried, evaporated in vacuo and the residue is distilled in high vacuum, whereby the 1-(1'-n-hexyl-4'-hydroxy-4'-piperidyl)-2-propanone with bpn 0o3 98° is obtained.

På analog måte oppnåes f. eks.: 1- (l'-n-dodecyl-4'-hydroxy-4'-piperidyl)-2- propanon, kpn m 135—138°, under anvendelse av 6 ml n-dodecylbromid; 1 - (1 '-cyklopropylmethyl-4'-hydroxy-4'-piperidyl)-2-propanon, under anvendelse av 5 g jodmethyl-cyklopropan (sammenlign J. Am. Chem. Soc. 85, 1886 (1963), og 1- [ 1'- (y-f enyl-propyl) -4'-hydroxy-4'-pi-peridyl]-2-propanon kpn 003 117—120° av 5 g y-fenyl-propyl-bromid. In an analogous manner is obtained, for example: 1-(1'-n-dodecyl-4'-hydroxy-4'-piperidyl)-2-propanone, mp 135-138°, using 6 ml of n-dodecyl bromide; 1 - (1'-cyclopropylmethyl-4'-hydroxy-4'-piperidyl)-2-propanone, using 5 g of iodomethyl-cyclopropane (compare J. Am. Chem. Soc. 85, 1886 (1963), and 1 - [1'-(γ-phenyl-propyl)-4'-hydroxy-4'-piperidyl]-2-propanone bp 003 117-120° from 5 g of γ-phenyl-propyl bromide.

Claims (1)

Fremgangsmåte til fremstilling av nye terapeutisk virksomme piperidinderivater med den generelle formel (I),Process for the preparation of new therapeutically active piperidine derivatives of the general formula (I), hvor R, betyr hydrogen, en alkylrest med i høyden 12 karbonatomer, en alkenylrest med 3—5 karbonatomer, cyklopropylmethylresten eller en fenyl-alkylrest med 7—9 karbonatomer, R2 hydrogen eller methylresten og R3 en alkylrest med i høyden 4 karbonatomer, fenylresten, en fenylalkylrest med 7—9 karbonatomer, styrylresten eller sammen med R, en eventuelt methyl-substituert trimethylen- til hexamet-hylenrest og R., hydrogen eller methyl- resten, og deres salter med uorganiske og organiske syrer, karakterisert ved at man fortrinnsvis ved 20° til 60°C omsetter a) et 4-piperidon med den generelle formel (II), med et keton med den generelle formel (III), R3-CO-CH2-R2 (III) hvor R,, R2, R3 og R, har den ovenfor angitte betydning, i nærvær av et i homogen eller heterogen fase foreliggende basisk eller surt stoff og eventuelt overfører den erholdte forbindelse med den generelle formel I til et salt med en uorganisk eller organisk syre, eller b) overfører et ketimin med den generelle formel (IV), hvor R5 betyr en hydrokarbonrest, og R2 og R3 har den under a) angitte betydning, til dets alkalimetallforbindelse, isærdeles het lithiumforbindelsen, omsetter sistnevnte med en forbindelse med den generelle formel (V), hvor Rt' har den under a) for R, angitte betydning med unntagelse av hydrogen og R, har den under a) angitte betydning, under vannfrie betingelser og hydrolyserer det erholdte addukt med den generelle formel (VI), hvor M betyr et alkalimetallatom, isærdeleshet et lithiumatom, og R,', R2, R3, R4 og R3 har den foran angitte betydning, under milde betingelser, fortrinnsvis i surt medium, og hvis ønsket overfører den erholdte forbindelse med den generelle formel I til et salt med en uorganisk eller organisk syre, eller c) behandler en forbindelse med den generelle formel hvor R/' betyr en rest tilsvarende den under a) angitte definisjon for R, eller benzyloxycarbonylresten og R3' hydrogen, eller en rest, som under tilføyelsen av methylengruppen -CH2- tilsvarer en under a) definert rest R.,, og Rg og R4 har den under a) angitte betydning, med en kvikksølvion-inneholdende vandig mineralsyre ved værelsetemperatur til moderat forhøyet temperatur og avspalter en forekommende benzyloxycarbonylrest R," ved hydrogenolyse og, hvis ønsket, over-fører den erholdte forbindelse med den generelle formel I til et salt med en uorganisk eller organisk syre, eller eventuelt omsetter en forbindelse med den foran a) angitte generelle formel 1, hvor R( betyr hydrogen og R2, R:i, og R4 har den der angitte betydning, med en reaksjonsdyktig ester av en forbindelse med den generelle formel (VIII), hvor R,' har den under b) angitte betydning, og, hvis ønsket, overfører den erholdte forbindelse med den generelle formel I til et salt med en uorganisk eller organisk syre.where R means hydrogen, an alkyl residue with a maximum of 12 carbon atoms, an alkenyl residue with 3-5 carbon atoms, the cyclopropylmethyl residue or a phenyl-alkyl residue with 7-9 carbon atoms, R2 hydrogen or the methyl residue and R3 an alkyl residue with a maximum of 4 carbon atoms, the phenyl residue, a phenylalkyl residue with 7-9 carbon atoms, the styryl residue or together with R, an optionally methyl-substituted trimethylene to hexamethylene residue and R., hydrogen or the methyl residue, and their salts with inorganic and organic acids, characterized in that preferably at 20° to 60°C a) a 4-piperidone with the general formula (II) is reacted, with a ketone of the general formula (III), R3-CO-CH2-R2 (III) where R1, R2, R3 and R1 have the meaning given above, in the presence of a basic or acidic substance present in a homogeneous or heterogeneous phase and optionally transfers the obtained compound of the general formula I to a salt with an inorganic or organic acid, or b) transfers a ketimine of the general formula (IV), where R5 means a hydrocarbon residue, and R2 and R3 have the meaning stated under a), to its alkali metal compound, in particular called the lithium compound, reacts the latter with a compound of the general formula (V), where Rt' has the meaning given under a) for R, with the exception of hydrogen and R has the meaning given under a), under anhydrous conditions and hydrolyzes the obtained adduct of the general formula (VI), where M means an alkali metal atom, in particular a lithium atom, and R,', R 2 , R 3 , R 4 and R 3 have the above meaning, under mild conditions, preferably in acidic medium, and if desired transfer the obtained compound of the general formula I to a salt with an inorganic or organic acid, or c) treat a compound of the general formula where R/' means a residue corresponding to the definition given under a) for R, or the benzyloxycarbonyl residue and R3' hydrogen, or a residue, which during the addition of the methylene group -CH2- corresponds to a residue defined under a) R.,, and Rg and R4 has the meaning given under a), with a mercury ion-containing aqueous mineral acid at room temperature to moderately elevated temperature and splits off an occurring benzyloxycarbonyl residue R" by hydrogenolysis and, if desired, transfers the obtained compound of the general formula I to a salt with an inorganic or organic acid, or optionally reacts a compound with the general formula 1 stated above a) where R( means hydrogen and R 2 , R 1 , and R 4 have the meaning indicated therein, with a reactive ester of a compound of the general formula (VIII), where R,' has the meaning specified under b), and, if desired, converts the obtained compound of the general formula I into a salt with an inorganic or organic acid.
NO801234A 1979-04-30 1980-04-28 ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE ISOPROPYLAMINO-PYRIMIDINE HYDROXY DERIVATIVES. NO154055C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB7914987 1979-04-30

Publications (3)

Publication Number Publication Date
NO801234L NO801234L (en) 1980-10-31
NO154055B true NO154055B (en) 1986-04-01
NO154055C NO154055C (en) 1986-07-09

Family

ID=10504858

Family Applications (2)

Application Number Title Priority Date Filing Date
NO801235A NO154056C (en) 1979-04-30 1980-04-28 ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE ISOPROPYLAMINO-PYRIMIDINE HYDROXY DERIVATIVES.
NO801234A NO154055C (en) 1979-04-30 1980-04-28 ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE ISOPROPYLAMINO-PYRIMIDINE HYDROXY DERIVATIVES.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO801235A NO154056C (en) 1979-04-30 1980-04-28 ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE ISOPROPYLAMINO-PYRIMIDINE HYDROXY DERIVATIVES.

Country Status (26)

Country Link
JP (2) JPS55145670A (en)
AR (2) AR222870A1 (en)
AT (2) AT380012B (en)
BE (2) BE882593A (en)
CH (2) CH645633A5 (en)
DK (2) DK183780A (en)
EG (2) EG14259A (en)
ES (2) ES8103061A1 (en)
FI (2) FI66358C (en)
FR (2) FR2455588A1 (en)
GB (2) GB2054556B (en)
HK (2) HK55583A (en)
IE (2) IE49709B1 (en)
IN (2) IN154066B (en)
IT (2) IT1141296B (en)
LU (2) LU82333A1 (en)
MA (1) MA18824A1 (en)
MX (2) MX5878E (en)
MY (2) MY8400204A (en)
NL (2) NL8002271A (en)
NO (2) NO154056C (en)
NZ (2) NZ193421A (en)
OA (2) OA06527A (en)
PT (2) PT71154A (en)
SG (2) SG22283G (en)
ZA (2) ZA801960B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63145595U (en) * 1987-03-13 1988-09-26
JPS645795U (en) * 1987-06-26 1989-01-13
JPH01100695U (en) * 1987-12-21 1989-07-06
US5264435A (en) * 1988-12-29 1993-11-23 Mitsui Petrochemical Industries, Ltd. Pyrimidines and their pharmaceutical acceptable salts, and their use as medicines
HU206337B (en) * 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
IT1141487B (en) 1986-10-01
SG22583G (en) 1983-12-16
AR222869A1 (en) 1981-06-30
IT1141296B (en) 1986-10-01
ZA801960B (en) 1981-04-29
JPS6116272B2 (en) 1986-04-28
IT8021542A0 (en) 1980-04-22
BE882593A (en) 1980-07-31
FR2455588A1 (en) 1980-11-28
SG22283G (en) 1983-12-16
FI801084A (en) 1980-10-31
IT8021543A0 (en) 1980-04-22
NO154056B (en) 1986-04-01
HK55683A (en) 1983-11-25
CH645361A5 (en) 1984-09-28
GB2054556B (en) 1983-01-26
ES8103060A1 (en) 1981-02-16
FI66358B (en) 1984-06-29
MY8400204A (en) 1984-12-31
ES491000A0 (en) 1981-02-16
NO154055C (en) 1986-07-09
ES490999A0 (en) 1981-02-16
EG14284A (en) 1983-09-30
CH645633A5 (en) 1984-10-15
DK183880A (en) 1980-10-31
FI66358C (en) 1984-10-10
JPS55145671A (en) 1980-11-13
IN154067B (en) 1984-09-15
GB2055801A (en) 1981-03-11
ATA221580A (en) 1985-08-15
NO801235L (en) 1980-10-31
FI801083A (en) 1980-10-31
NZ193422A (en) 1981-12-15
OA06525A (en) 1981-07-31
IN154066B (en) 1984-09-15
FR2455589A1 (en) 1980-11-28
NL8002271A (en) 1980-11-03
ZA801958B (en) 1981-04-29
ATA221680A (en) 1985-08-15
FR2455588B1 (en) 1983-04-15
AT380012B (en) 1986-03-25
GB2055801B (en) 1983-02-09
JPS55145670A (en) 1980-11-13
NO154056C (en) 1986-07-09
NO801234L (en) 1980-10-31
GB2054556A (en) 1981-02-18
PT71155A (en) 1980-05-01
AR222870A1 (en) 1981-06-30
JPS6116273B2 (en) 1986-04-28
OA06527A (en) 1981-07-31
BE882594A (en) 1980-07-31
IE800864L (en) 1980-10-30
MX5878E (en) 1984-08-16
EG14259A (en) 1983-09-30
IE800865L (en) 1980-10-30
NL8002272A (en) 1980-11-03
MY8400203A (en) 1984-12-31
PT71154A (en) 1980-05-01
FI66359C (en) 1984-10-10
FR2455589B1 (en) 1981-07-10
DK183780A (en) 1980-10-31
ES8103061A1 (en) 1981-02-16
MX6514E (en) 1985-06-26
NZ193421A (en) 1981-11-19
AT380013B (en) 1986-03-25
MA18824A1 (en) 1980-12-31
IE49709B1 (en) 1985-11-27
IE49591B1 (en) 1985-10-30
HK55583A (en) 1983-11-25
LU82332A1 (en) 1980-07-02
LU82333A1 (en) 1980-07-02
FI66359B (en) 1984-06-29

Similar Documents

Publication Publication Date Title
Kuehne et al. Reactions of ynamines
CA1119601A (en) Tetrahydropyridine and piperidine derivatives and their acid addition salts, processes for their preparation and pharmaceutical preparations containing such compounds
US4243807A (en) 4-Phenoxymethyl-piperidines
CA1321792C (en) Piperidine opioid antagonists
US5039803A (en) Process for preparing aryl-substituted piperidines
US3366638A (en) 1-(1&#39;-hydrocarbyl substituted-4&#39;-hydroxy-4&#39;-piperidyl)-2-ketones
NO118219B (en)
NO130680B (en)
US3462444A (en) Novel 4-benzylpiperidine derivatives
CA1120036A (en) 4-(naphthylmethyl)piperidine derivatives
OA10694A (en) Processes and intermediates for preparing 1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine.
EP0057870B1 (en) N-optionelly substituted-2-amino-alpha-phenylphenethylamines and a method for their preparation
NO154055B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE ISOPROPYLAMINO-PYRIMIDINE HYDROXY DERIVATIVES.
US3518276A (en) Substituted 1-benzoylpropyl-4-hydroxy-4-phenyl piperidine derivatives
US4542132A (en) Cardiac stimulating cyclic sulfonamido substituted 4-piperidino-quinazoline derivatives, compositions, and method of use therefor
NO137782B (en) ANALOGICAL PROCEDURE FOR THE PREPARATION OF NEW PHARMACOLOGICALLY ACTIVE AMINO-PHENYL-ETHANOLAMINES
WO2007108011A2 (en) Process for the preparation of highly pure donepezil
US4210655A (en) Anti-depressant benzofuranyl piperidines
JP2011522845A (en) Aralkyl alcohol piperidine derivatives and their use as antidepressant drugs
US7446203B2 (en) Preparation of intermediates for acetycholinesterase inhibitors
US3158609A (en) Diphenylmethyl-1-aminopiperidine hydrazones and congeners
CN100467449C (en) Cyclic aminophenyl sulfamate derivative
DE1670186A1 (en) Process for the preparation of p-alkoxypiperidine amides
NO121212B (en)
NO131173B (en)